Search

Displaying results 6051 - 6060 of 6279 in total
  1. Drug

    Eniluracil

    go.drugbank.com/drugs/DB03516
    Investigational

    Eniluracil could improve 5-FU by increasing its effectiveness, reducing its side effects and/or making it orally available.

  2. Drug

    PPI-2458

    go.drugbank.com/drugs/DB05864
    Investigational

    PPI-2458 represents a potentially new and important addition to the growing list of therapeutics aimed at specific molecular oncology targets.

  3. Drug

    Chlorotoxin I-131

    go.drugbank.com/drugs/DB05462
    Investigational

    It is a synthetic version of a neurotoxin isolated from the venom of the Giant Yellow Israeli scorpion Leiurus quinquestriatus.

    Synonyms: I(131)-TM-601 (chlorotoxin)
  4. Drug

    ZYCOV-D

    go.drugbank.com/drugs/DB15892
    Experimental

    Once the plasmid DNA is introduced into host cells and the viral protein is translated, it elicits a strong immune response, stimulating the humoral and cellular components of the immune system[L16503]

  5. Drug

    BBV152

    go.drugbank.com/drugs/DB15847
    Investigational

    Animal studies in mice, rats, and rabbits reported BBV152 immunogenicity at two separate antigen concentrations with both types of adjuvants.

  6. Drug

    TRC093

    go.drugbank.com/drugs/DB06356
    Investigational

    TRC093 is a recombinant humanized IgG1k monoclonal antibody.

  7. Drug

    Smilagenin

    go.drugbank.com/drugs/DB05450
    Investigational

    Pre-clinical work with smilagenin showed it to be neuroprotective against betya-amyloid and glutamate damage which contributes to Alzheimer's disease and reverses the changes in the area of the brain involved

  8. Drug

    UB-612

    go.drugbank.com/drugs/DB16444
    Investigational

    It was able to reduce viral load and prevent COVID-19 infection in a mouse challenge model and in rhesus macaques[L30653, L30658].

  9. Drug

    Anti-SARS-CoV-2 REGN-COV2

    go.drugbank.com/drugs/DB15691
    Investigational

    Regeneron's clinical trial will study the effects of this drug on hospitalized COVID-19 patients, symptomatic COVID-19 patients (non-hospitalized), and uninfected individuals at high-risk of infection,

  10. Drug

    PI-0824

    go.drugbank.com/drugs/DB05516
    Investigational

    It is hoped that use of PI-0824 will reduce or potentially eliminate the need for high dose steroids and drugs that suppress the immune system.